Multiparametric Assays for Accelerating Early drug discovery

Herholt, Alexander; Galinski, Sabrina; Geyer, Philipp E.; Rossner, Moritz J.; Wehr, Michael C.

doi:10.1016/j.tips.2020.02.005

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Multiparametric Assays for Accelerating Early drug discovery

MPS-Authors

/persons/resource/persons196483

Geyer, Philipp E.
Mann, Matthias / Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Herholt, A., Galinski, S., Geyer, P. E., Rossner, M. J., & Wehr, M. C. (2020). Multiparametric Assays for Accelerating Early drug discovery. TRENDS IN PHARMACOLOGICAL SCIENCES, 41(5), 318-335. doi:10.1016/j.tips.2020.02.005.

Cite as: https://hdl.handle.net/21.11116/0000-0006-56AC-8

Abstract

Drug discovery campaigns are hampered by substantial attrition rates largely due to a lack of efficacy and safety reasons associated with candidate drugs. This is true in particular for genetically complex diseases, where insufficient knowledge of the modulatory actions of candidate drugs on targets and entire target pathways further adds to the problem of attrition. To better profile compound actions on targets, potential off-targets, and disease-linked pathways, new innovative technologies need to be developed that can elucidate the complex cellular signaling networks in health and disease. Here, we discuss progress in genetically encoded multiparametric assays and mass spectrometry (MS)-based proteomics, which both represent promising toolkits to profile multifactorial actions of drug candidates in disease-relevant cellular systems to promote drug discovery and personalized medicine.